Financial

AstraZeneca rejects final proposal from Pfizer

Monday, 19 May 2014

The Board of AstraZeneca PLC notes the announcement by Pfizer Inc. of its final proposal to combine the two companies. Leif Johansson, Chairman of AstraZeneca mentioned that the final proposal is a minor improvement which continues to fall short of the Board's view of value and has been rejected.

Pfizer announcement and AstraZeneca statement

Tuesday, 13 May 2014

Pfizer wishes to enter into discussions with AstraZeneca regarding a potential combination of the two companies and is "disappointed at the lack of engagement by the AstraZeneca Board". The Board of AstraZeneca notes the announcement made by Pfizer and states that the "announcement contains no new proposal nor substantive new information."

Forest Laboratories to Acquire Clinical Data, Inc.

Wednesday, 23 February 2011

Forest Laboratories, Inc. (Forest) (NYSE: FRX) and Clinical Data, Inc. (Clinical Data) (NASDAQ: CLDA) have entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics,

Convergence Pharmaceuticals Successfully Launched out of GSK to Focus on Novel High Value Analgesics

Thursday, 07 October 2010

Convergence Pharmaceuticals Ltd, a new company focused on the development of novel and high value analgesic medicines, was officially launched and has successfully raised $35.4 million (£22.4 million) in Series A financing from a syndicate of leading European and US life science investors. Convergence Pharmaceuticals is an independent biotechnology company that has acquired clinical assets from GlaxoSmithKline ("GSK").

Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business

Friday, 16 July 2010

Mylan Inc. (Nasdaq: MYL) has announced plans to acquire Bioniche Pharma Holdings Limited, a privately held, global injectable pharmaceutical company for $550 million in cash.

Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.

Thursday, 20 May 2010

Astellas Pharma Inc. (TSE: 4503), a global pharmaceutical company, and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP), a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity, have entered into a definitive merger agreement under which Astellas will acquire OSI.

ratiopharm to become the hub for Teva's European growth strategy

Monday, 29 March 2010

The ratiopharm Group gets a new owner. Subsequent to an extensive bidding process, the Israel-based company Teva Pharmaceutical Industries Ltd. is going to acquire the Ulm based company from Merckle Group's VEM asset management. The agreed enterprise value is € 3.625 billion.